Glycomics in Canada receives crucial funding boost to further life-saving research and biotechnology development.
Category: Press Release
Glycomics is an integral part of ABOzymes’ life-saving research and technology development.
This collaboration combines Alectos’ expertise in small-molecule therapeutics with Biogen’s development capabilities in movement disorders.
This investment will support state-of-the-art health research for Canada’s leading diseases, including cancer, diabetes, dementia, muscular dystrophy and universal donor blood.
As a member of BIOTECanada’s network, GlycoNet aims to mobilize glycomics research into tangible and sustainable innovation for Canadians.
The collaborative project is partnered with CQDM, Simon Fraser University, Amgen, Merck, and Servier.
Genetic disease research has benefitted substantially from the study of glycomics, which relates to the functions of glycans, or sugar, in biological systems
The Network will commit $1.8 million in glycomics to support made-in-Canada health innovations and build a sustainable national bioeconomy
Project funded through CQDM Quantum Leap program with support from Merck and GlycoNet will exploit new drug development platform
$1.3 million in funding to support new sugar research to tackle unmet needs in national healthcare